1
<b>I</b>
· • [
Haring.
: <sub>[]</sub>
لِيا
I
:0
##
===
Ľ
: II
1
; ===;

1	CLAIMS
2	What is claimed is:
3	
4	Claim 1. A method for treating a patient suffering from
5	a cancerous disease comprising:
6	administering to said patient anti-cancer antibodies or
7	fragments thereof produced in accordance with a method for
8	the production of individually customized anti-cancer
9	antibodies which are useful in treating a cancerous disease,
10	said antibodies including a subset of antibodies or fragments
11	thereof characterized as being cytotoxic against cells of a
12	cancerous tissue, said subset being essentially benign to
13	non-cancerous cells;
14	wherein one or more antibodies or fragments thereof
15	selected from said subset are placed in admixture with a
16	pharmaceutically acceptable adjuvant and are administered in
17	an amount effective to mediate treatment of said cancerous
18	disease.
19	
20	Claim 2. The method for treating a patient suffering
21	from a cancerous disease in accordance with claim 1, wherein
22	said one or more antibodies or fragments thereof selected
23	from said subset are humanized.
24	

1	Claim 3. The method for treating a patient suffering
2	from a cancerous disease in accordance with claim 1
3	comprising:
4	conjugating said subset of antibodies or fragments
5	thereof with a member selected from the group consisting of
6	toxins, enzymes, radioactive compounds, and hematogenous
7	cells; and
8	administering conjugated antibodies or fragments thereof
9	to said patient;
10	wherein said conjugated antibodies are placed in
11	admixture with a pharmaceutically acceptable adjuvant and are
12	administered in an amount effective to mediate treatment of
13	said cancerous disease.
14	
15	Claim 4. The method of claim 3, wherein said one or
16	more antibodies or fragments thereof selected from said
17	subset are humanized.
18	
19	Claim 5. The method for treating a patient suffering
20	from a cancerous disease in accordance with claim 1 wherein:
21	the cytotoxicity of said antibodies or fragments thereof
22	is mediated through antibody dependent cellular toxicity.
23	
24	Claim 6. The method for treating a patient suffering
25	from a cancerous disease in accordance with claim 1 wherein:

1	the cytotoxicity of said antibodies or fragments thereof
2	is mediated through complement dependent cellular toxicity.
3	
4	Claim 7. The method for treating a patient suffering
5	from a cancerous disease in accordance with claim 1 wherein:
6	the cytotoxicity of said antibodies or fragments thereof
7	is mediated through catalyzing of the hydrolysis of cellular
8	chemical bonds.
9	
10	Claim 8. The method for treating a patient suffering
11	from a cancerous disease in accordance with claim 1 wherein:
12	the cytotoxicity of said antibodies or fragments thereof
13	is mediated through producing an immune response against
14	putative cancer antigens residing on tumor cells.
15	
16	Claim 9. The method for treating a patient suffering
17	from a cancerous disease in accordance with claim 1 wherein:
18	the cytotoxicity of said antibodies or fragments thereof
19	is mediated through targeting of cell membrane proteins to
20	interfere with their function.
21	
22	Claim 10. The method for treating a patient suffering
23	from a cancerous disease in accordance with claim 1 wherein:
24	the cytotoxicity of said antibodies or fragments thereof
25	is mediated through production of a conformational change in

1	a cellular protein effective to produce a signal to initiate
2	cell-killing.
3	
4	Claim 11. The method for treating a patient suffering
5	from a cancerous disease in accordance with claim 1 wherein:
6	said method of production utilizes a tissue sample
7	containing cancerous and non-cancerous cells obtained from a
8	particular individual.
9	
10	Claim 12. The method for treating a patient suffering
11	from a cancerous disease in accordance with claim 1 wherein:
12	the antibodies or fragments thereof are selected from
13	the group consisting of a 3BD-3, a 3BD-6, a 3BD-8, a 3BD-9, a
14	3BD-15, a 3BD-25, a 3BD-26 and a 3BD-27 monoclonal antibody
15	or combinations thereof.
16	
17	Claim 13. The method for treating a patient suffering
18	from a cancerous disease in accordance with claim 1 wherein:
19	the antibodies or fragment thereof are produced by one
20	or more hybridoma cell lines having an ATCC Accession Number
21	selected from the group consisting of ( ).
22	
23	Claim 14. The method for treating a patient suffering
24	from a cancerous disease in accordance with claim 1 wherein:
25	the antibodies or fragments thereof are selected from
26	the group consisting of a 1LN-1, a 1LN-12, a 1LN-14, a 2LN-

21, a 2LN-28, a 2LN-29, a 2LN-31, a 2LN-33, a 2LN-34 and a 2LN-35 monoclonal antibody or combinations thereof. Claim 15. The method for treating a patient suffering from a cancerous disease in accordance with claim 1 wherein: the antibodies or fragments thereof are produced by one or more hybridoma cell lines having an ATCC Accession Number selected from the group consisting of (